D-0370-2022 Class II Terminated
FDA drug recall D-0370-2022 was initiated by Teva Pharmaceuticals USA on Dec 31, 2021 and is designated Class II. Reason for recall: Lack of Assurance of Sterility The recall status is terminated (terminated Jun 4, 2024). Affected quantity: 7,400 cartons.
Recall details
- Product Type
- Drugs
- Report Date
- Jan 19, 2022
- Initiation Date
- Dec 31, 2021
- Termination Date
- Jun 4, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 7,400 cartons
Product description
MethylPREDNISolone Acetate Injectable Suspension USP 400 mg/10mL (40mg/mL), 10 mL Multiple-Dose Vial, Rx Only, Manufactured for: Northstar Rx LLC, Memphis, TN 38141, Manufactured By: Teva Pharmaceuticals USA, Inc., Parsippany, NJ 07054, NDC 16714-090-01, packaged in cartons.
Reason for recall
Lack of Assurance of Sterility
Distribution pattern
Methylprednisolone, TN Norepinephrine BItartrate - MS, OH
Code information
Lot # 100022393, exp 09/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0370-2022
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026